Send to:

Choose Destination
See comment in PubMed Commons below
J Cyst Fibros. 2013 Jan;12(1):49-53. doi: 10.1016/j.jcf.2012.05.010. Epub 2012 Jul 15.

A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic.

Author information

  • 1Department of Cystic Fibrosis, Royal Brompton & Harefield NHS Foundation Trust, London, UK.



Azithromycin is widely used as an immunomodulatory agent in the treatment of cystic fibrosis with previous literature documenting improvements in lung function and a reduction in infective exacerbations. The maximal study period in adults has been six months.


81 adult patients taking continuous azithromycin were retrospectively identified. Percentage predicted FEV(1) and courses of intravenous antibiotics were examined at yearly intervals two years prior to and two years after azithromycin initiation.


FEV(1) deteriorated in the two years before starting azithromycin by a mean of 2.02% per year. In the year following initiation, FEV(1) increased by 1.15% (P=0.01). However, a mean 2.58% reduction was observed in year two. There was no statistically significant effect on courses of intravenous antibiotics.


Azithromycin resulted in an improved FEV(1) at year one. This effect was not sustained beyond the first year of treatment.

Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk